Breaking News Instant updates and real-time market news.

EGO

Eldorado Gold

$9.16

(0.00%)

, NEM

Newmont Goldcorp

$39.33

(0.00%)

09:40
08/26/19
08/26
09:40
08/26/19
09:40

Unusually active option classes on open August 26th

Unusual total active option classes on open include: Eldorado Gold (EGO), Newmont Mining (NEM), Bristol Myers Squibb (BMY), Barrick Gold (GOLD), SPDR S&P Biotech (XBI), Boeing (BA), Cleveland-Cliffs (CLF), Advanced Micro (AMD), Diamond ETF (DIA), and Salesforce (CRM).

EGO

Eldorado Gold

$9.16

(0.00%)

NEM

Newmont Goldcorp

$39.33

(0.00%)

BMY

Bristol-Myers

$46.59

(0.00%)

GOLD

Barrick Gold

$19.14

(0.00%)

XBI

SPDR S&P BIOTECH

$79.40

(0.00%)

BA

Boeing

$356.11

(0.00%)

CLF

Cleveland-Cliffs

$7.98

(0.00%)

AMD

AMD

$29.55

(0.00%)

DIA

Diamonds Fund ETF

$256.37

(0.00%)

CRM

Salesforce

$151.50

(0.00%)

  • 27

    Aug

  • 28

    Aug

  • 28

    Aug

  • 03

    Sep

  • 09

    Sep

  • 09

    Sep

  • 10

    Sep

  • 16

    Sep

  • 23

    Sep

  • 12

    Dec

  • 16

    Dec

EGO Eldorado Gold
$9.16

(0.00%)

07/11/19
CIBC
07/11/19
DOWNGRADE
CIBC
Neutral
Eldorado Gold downgraded to Neutral from Outperformer at CIBC
07/23/19
NATB
07/23/19
DOWNGRADE
NATB
Sector Perform
Eldorado Gold downgraded to Sector Perform from Outperform at National Bank
07/23/19
MITR
07/23/19
DOWNGRADE
MITR
Hold
Eldorado Gold downgraded to Hold from Buy at GMP Securities
07/10/19
CIBC
07/10/19
UPGRADE
CIBC
Neutral
Eldorado Gold upgraded to Neutral from Underperformer at CIBC
NEM Newmont Goldcorp
$39.33

(0.00%)

05/23/19
SBSH
05/23/19
NO CHANGE
Target $12.5
SBSH
Neutral
Citi upgrades Newmont, downgrades Barrick on resumption of coverage
Citi analyst Alexander Hacking resumed coverage of Barrick Gold and downgraded the shares to Neutral from Buy while lowering his price target to $12.50 from $14. He also resumed coverage of Newmont Mining (NEM) and upgraded the shares to Buy from Neutral while raising his price target for the shares to $40 from $36. The gold sector remains challenged, but Newmont offers better value than Barrick, Hacking tells investors in a research note. After applying Barrick's 1.2 times multiple to Newmont's holdings in the joint venture assets, the analyst sees Newmont's other assets trading at only 0.76 times net asset value. This could be re-rated higher as the market starts to incorporate the joint venture into models, says Hacking.
08/15/19
SBSH
08/15/19
NO CHANGE
SBSH
Buy
Newmont underperformance relative to peers overdone, says Citi
Newmont Goldcorp shares has underperformed the gold group by 20%-30% since the Goldcorp (GG) deal was announced, Citi analyst Alexander Hacking tells investors in a research note. This seems "highly punitive," says the analyst, who views the underperformance as overdone. His "back-of-envelope" analysis implies a market value of the Goldcorp assets of $6B with gold at $1,530 or ounce versus the $10B that Newmont paid with gold at $1,280 per ounce. Hacking reiterates a Buy rating on Newmont shares.
07/03/19
BMOC
07/03/19
DOWNGRADE
Target $45
BMOC
Market Perform
Newmont Goldcorp resumed with a Market Perform from Outperform at BMO Capital
BMO Capital analyst Andrew Kaip downgraded Newmont Goldcorp to Market Perform from Outperform after resuming coverage of the name. He raised his price target for the shares to $45 from $42. While both the acquisition of Goldcorp and the formation of the Nevada joint venture have been accretive events, near-term investor uncertainty regarding the Goldcorp transaction, compounded by recent events at Musselwhite and Penasquito, are likely to "temper investor interest" until Newmont Goldcorp is able to demonstrate value, Kaip tells investors in a research note. As such, the analyst remains cautious until Newmont "demonstrates progress."
07/03/19
BMOC
07/03/19
UPGRADE
Target $20
BMOC
Outperform
Barrick Gold resumed with an Outperform from Market Perform at BMO Capital
BMO Capital analyst Andrew Kaip upgraded Barrick Gold (GOLD) to Outperform from Market Perform and raised his price target for the shares to $20 from $14.50 after resuming coverage of the name. The formation of the Nevada joint venture is a positive for Barrick as the synergies derived from consolidating the Nevada operations with Newmont Goldcorp (NEM) "unlock value," Kaip tells investors in a research note. The analyst this morning also downgraded Newmont Goldcorp to Market Perform from Outperform. He's confident the near-term benefits of the venture outweigh the risks for Barrick.
BMY Bristol-Myers
$46.59

(0.00%)

08/09/19
WBLR
08/09/19
NO CHANGE
WBLR
William Blair an 'aggressive' buyer of Nektar on today's 37% selloff
William Blair analyst Andy Hsieh is an "aggressive" buyer of Nektar Therapeutics (NKTR) on today's selloff. The stock is down after management disclosed that the scope of collaboration with partner Bristol-Myers (BMY) is now narrowed to roughly five or six registrational trials from the planned 18 first announced in January of this year, and that there were some issues pertaining to the manufacturing of bempegaldesleukin that potentially led to the drastic difference in response rate between the November 2017 and June 2018 data announcement of the Phase II PIVOT-02 results, Hsieh tells investors in a research note. While acknowledging that the development is "directionally negative," the analyst believes the magnitude of the Nektar selloff overshoots the potential impact. In addition, Nektar is working with the FDA and partner Bristol-Myers to resolve the manufacturing issue by establishing new quality control initiatives, Hsieh points out. He believes empegaldesleukin "remains differentiated" and he keeps an Outperform rating on Nektar Therapeutics. The stock in premarket trading is down 37%, or $10.92, to $18.65.
08/19/19
MZHO
08/19/19
DOWNGRADE
MZHO
Neutral
Amgen, Celgene downgraded to Neutral on valuation at Mizuho
As previously reported, Mizuho analyst Salim Syed downgraded Amgen (AMGN) and Celgene (CELG), each to Neutral from Buy, "solely" on the stock's current trading prices nearing what the analyst views as appropriate valuations. Amgen has run up over the last week by about 10% following a "very clean Enbrel litigation win," but the stock price now gives full credit for its Enbrel IP, said Syed, who raised his price target on Amgen shares to $212 from $208. He also cut his price target on Celgene shares to $100 from $103, based on a calculation of one Bristol-Myers (BMY) share being worth $47, plus $50 cash per share and $3 for a risk-adjusted CVR valuation.
08/14/19
08/14/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Evercore Partners (EVR) upgraded to Neutral from Sell at Goldman Sachs with analyst Richard Ramsden saying believes that stronger U.S. large cap deal activity than he previously expected should support Evercore's revenues. 2. Sanofi (SNY) upgraded to Buy from Neutral at UBS with analyst Laura Sutcliffe saying she sees signs of a turnaround for the company and believes its pipeline can fixed ahead of patent expiration. 3. Bristol-Myers (BMY) upgraded to Overweight from Neutral at Atlantic Equities. 4. Horizon Pharma (HZNP) upgraded to Outperform from Market Perform at BMO Capital with analyst Gary Nachman citing the company's "strong" Q2 results driven by Krystexxa. 5. Ferrari (RACE) upgraded to Buy from Neutral at Goldman Sachs with analyst George Galliers citing the company's Q2 results earlier this month. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/14/19
ATLE
08/14/19
UPGRADE
Target $63
ATLE
Overweight
Bristol-Myers upgraded to Overweight from Neutral at Atlantic Equities
Atlantic Equities analyst Steve Chesney upgraded Bristol-Myers Squibb to Overweight from Neutral and raised his price target for the shares to $63 from $51.
GOLD Barrick Gold
$19.14

(0.00%)

08/13/19
ARGS
08/13/19
UPGRADE
Target $22
ARGS
Buy
Barrick Gold upgraded to Buy from Hold at Argus
Argus analyst David Coleman upgraded Barrick Gold to Buy with a price target of $22, citing the management's upwardly revised output guidance and his expectations of higher gold prices in the coming quarters. The analyst also expects Barrick Gold to benefit from the recent Randgold acquisition and expects higher earnings over time.
07/16/19
LEHM
07/16/19
DOWNGRADE
Target $18
LEHM
Equal Weight
Barrick Gold downgraded to Equal Weight on valuation at Barclays
Barclays analyst Matthew Murphy downgraded Barrick Gold to Equal Weight from Overweight while raising his price target for the shares to $18 from $15. The analyst cites valuation for the downgrade. While Murphy increased his gold multiples, he's "somewhat cautious of a retracement" and is "not calling for unbridled upside."
07/16/19
LEHM
07/16/19
DOWNGRADE
LEHM
Equal Weight
Barrick Gold downgraded to Equal Weight from Overweight at Barclays
Barclays analyst Matthew Murphy downgraded Barrick Gold to Equal Weight from Overweight.
08/13/19
ARGS
08/13/19
UPGRADE
ARGS
Buy
Barrick Gold upgraded to Buy from Hold at Argus
XBI SPDR S&P BIOTECH
$79.40

(0.00%)

03/12/19
PIPR
03/12/19
NO CHANGE
PIPR
Biopharma stocks should be up sharply on Sharpless selection, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond said he expects biopharma stocks to be up sharply on news that former National Cancer Institute director Ned Sharpless will be named acting FDA commissioner. The biotech sector "experienced a swoon of sorts" since Scott Gottlieb announced his departure, but with the announcement of Gottlieb's favored choice as successor Raymond believes the FDA will remain "on its current industry-friendly and efficiency driven trajectory," the analyst tells investors.
BA Boeing
$356.11

(0.00%)

08/06/19
NBLE
08/06/19
UPGRADE
Target $50
NBLE
Outperform
Ducommun upgraded to Outperform from Market Perform at Noble Capital
Noble Capital analyst Christian Herbosa upgraded Ducommun (DCO) to Outperform from Market Perform after the company reported higher than expected sales and otherwise strong performance in Q2. Despite ongoing delays in the return to service of Boeing's (BA) 737 MAX, which had been a key growth driver for Ducommun in Q2, management is confident that the company can achieve 7%-9% revenue growth across commercial aerospace and military platforms for the rest of the year, noted Herbosa. He set a $50 price target on Ducommun shares.
08/13/19
08/13/19
DOWNGRADE

Hold
Southwest downgraded to Hold from Buy at Argus
As previously reported, Argus analyst John Staszak downgraded Southwest (LUV) to Hold, citing serious operational disruption and rising costs from Boeing's (BA) continued grounding of the 737 MAX aircraft at a time of "solid" flight demand. The analyst notes that although the stock is trading near the low end of its 5-year historical range at 11.4-times his expected 2019 earnings, he sees its valuation as reflective of the company's near term prospects for higher costs and weaker profitability.
08/22/19
BUCK
08/22/19
NO CHANGE
Target $395
BUCK
Neutral
Boeing remains a tactical buying opportunity, says Buckingham
Buckingham analyst Richard Safran reiterated his belief that Boeing remains a tactical buying opportunity and thinks the stock could go to $400-$450 driven primarily by a 9% free cash flow yield based on roughly $30/share in free cash flow in 2020. In a research note to investors, Safran says he thinks that Boeing hiring hundreds of temporary workers at its Moses Lake facility and expanding its delivery capacity is a positive sign that Boeing has confidence achieving its early fourth quarter guide for the MAX to return to service. The analyst maintains a Neutral rating and $395 price target.
08/06/19
RHCO
08/06/19
NO CHANGE
Target $26
RHCO
Sell
Astronics price target lowered to $26 from $35 at SunTrust
SunTrust analyst Michael Ciarmoli lowered his price target on Astronics (ATRO) to $26 and kept his Sell rating after its Q2 earnings miss and below-consensus FY19 revenue guidance. The analyst cites weak aerospace bookings as an "ominous sign" reflecting his concerns about channel destocking in addition to the company's exposure to Boeing's (BA) 737 MAX aircraft issues. Ciarmoli added that Astronics' disclosure of a satellite failure "derailing" its AeroSat antenna opportunity was an incremental negative surprise.
CLF Cleveland-Cliffs
$7.98

(0.00%)

04/26/19
FBCO
04/26/19
UPGRADE
Target $14
FBCO
Outperform
Cleveland-Cliffs upgraded to Outperform from Neutral at Credit Suisse
Credit Suisse analyst Curt Woodworth upgraded Cleveland-Cliffs to Outperform from Neutral and raised his price target to $14 from $13 following the company's Q1 results. In a research note to investors, Woodworth says he sees potential value near $16-$18 once the HBI plant is fully ramped, even with low hot-rolled coil prices at that point in time. He also forecasts substantially higher NAV uplift from HBI and now models EBITDA accretion of roughly $200M.
04/26/19
04/26/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Cleveland-Cliffs (CLF) upgraded to Outperform from Neutral at Credit Suisse with analyst Curt Woodworth saying he sees potential value near $16-$18 once the HBI plant is fully ramped, even with low hot-rolled coil prices at that point in time. 2. Argo Group (ARGO) upgraded to Outperform from Market Perform at William Blair with analyst Adam Klauber saying Argo is beginning to emerge as a long-term midcap growth insurer, Klauber tells investors in a research note. 3. Illinois Tool Works (ITW) upgraded to Neutral from Underweight at JPMorgan with analyst Ann Duignan saying following the company's "solid" Q1 results, downside risk to 2019 earnings estimates "appears limited," with the worst of auto builds and European weakness "likely behind us." 4. The Medicines Co. (MDCO) upgraded to Buy from Neutral at Goldman Sachs while Esperion (ESPR) upgraded to Neutral from Sell. 5. Shutterfly (SFLY) upgraded to Outperform from Market Perform at Raymond James with analyst Aaron Kessler citing stable Consumer segment growth trends and his expectation for improved consumer growth throughout 2019, as well as "very achievable" 2021 EBITDA guidance of $400M-$450M with modest organic growth assumptions and modest Lifetouch synergies baked in. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
05/13/19
KEYB
05/13/19
NO CHANGE
KEYB
Chinese tariffs negative for Schnitzer Steel, positive for Luxfer, says KeyBanc
KeyBanc analyst Philip Gibbs notes that the Trump administration announced the U.S. will be ratcheting up import tariffs to 25% from 10% on about $200B worth of Chinese goods. All else equal, Gibbs sees this as a modest negative for steel producers as key consumables remain sticky, and a relative neutral for ArcelorMittal (MT) given its global exposure. On steelmaking raw materials, the analyst sees this as a neutral for Cleveland-Cliffs (CLF) and a negative for Schnitzer Steel (SCHN), with the latter in the heart of challenged non-ferrous export markets. He also views this largely as a neutral for distributors, with perhaps a modest positive of Worthington's (WOR) Cylinders segment. Clearer winners appear to be Global Brass and Copper (BRSS), Luxfer (LXFR), and Materion (MTRN), whereby it will be tougher for the Chinese to compete within the U.S. in its core businesses.
06/26/19
JEFF
06/26/19
NO CHANGE
JEFF
Nucor flat rolled price increase likely to help sentiment, says Jefferies
After Nucor (NUE) announced a $40/t flat rolled price increase yesterday, which was the first increase since February, Jefferies analyst Martin Englert said he thinks peers are likely to follow. While the increase may not immediately raise prices, it is a move in the right direction that aids more positive sector sentiment, Englert tell investors. The analyst, who advises investors to increase exposure to steel stocks, names Nucor, Steel Dynamics (STLD), Cleveland-Cliffs (CLF) and Commercial Metals (CMC) as his top U.S. picks Other publicly traded companies in the steel space include AK Steel (AKS), ArcelorMittal (MT), TimkenSteel (TMST) and U.S. Steel (X).
AMD AMD
$29.55

(0.00%)

08/19/19
08/19/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. NXP Semiconductors (NXPI) initiated with an Outperform at Raymond James. 2. AMD (AMD) initiated with a Neutral at Piper Jaffray. 3. Sunnova Energy (NOVA) initiated with an Overweight at JPMorgan, as well as a Buy at Goldman Sachs and BofA/Merrill. 4. Chevron (CVX), Hess Corp. (HES), and ConocoPhillips (COP) initiated with Overweight ratings at Barclays while Exxon Mobil (XOM) and Occidental Petroleum (OXY) initiated with Equal Weight ratings. 5. Castle Biosciences (CSTL) initiated with an Outperform at SVB Leerink and Baird, as well as a Buy at Canaccord and BTIG. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
08/13/19
08/13/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Simply Good Foods (SMPl) initiated with an Outperform at Bernstein. 2. AMD (AMD) and Intel (INTC) initiated with a Hold at Loop Capital. 3. Cronos Group (CRON) initiated with an Overweight at Piper Jaffray. 4. Medallia (MDLA) initiated with an Outperform at William Blair, Wells Fargo, and Oppenheimer, a Buy at Roth Capital, Needham, and BofA/Merrill, as well as a Neutral at Credit Suisse and Citi. 5. Sempra Energy (SRE) initiated with an Equal Weight at Barclays. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
08/19/19
PIPR
08/19/19
INITIATION
Target $33
PIPR
Neutral
AMD initiated with a Neutral at Piper Jaffray
Piper Jaffray analyst Harsh Kumar initiated AMD with a Neutral rating and a price target of $33, saying that while the company offers an "exciting" product portfolio, he sees its current valuation as fair following a 69% year-to-date stock price run-up. The analyst contends that AMD's data center and gaming markets are undergoing secular long-term growth and offers a positive view of its "steady cadence" of new product ramps, but also sees "limited upside" for the stock given the uncertainty of the current macro and geopolitical environment.
08/16/19
NORL
08/16/19
UPGRADE
NORL
Market Perform
Northland upgrades Intel to Market Perform with AMD server launch in rear view
As previously reported, Northland analyst Gus Richard upgraded Intel (INTC) to Market Perform from Underperform as he noted that the negative AMD (AMD) server launch catalyst has now passed and he thinks a value stock such as Intel has odds of outperforming higher multiple stocks during selloffs. He also noted that sentiment on Intel is "nearing a low point."
DIA Diamonds Fund ETF
$256.37

(0.00%)

CRM Salesforce
$151.50

(0.00%)

08/23/19
ADAM
08/23/19
NO CHANGE
Target $185
ADAM
Buy
Salesforce price target raised to $185 from $175 at Canaccord
Canaccord analyst Richard Davis raised his price target on Salesforce to $185 from $175 following solid Q2 results. The analyst said the results were good in every metric that mattered allayed investor fears of a slowdown. Davis and likes its reasonable current valuation and reiterated his Buy rating on Salesforce shares.
08/23/19
RBCM
08/23/19
NO CHANGE
Target $200
RBCM
Outperform
Salesforce price target raised to $200 from $181 at RBC Capital
RBC Capital analyst Alex Zukin assumed the coverage and raised his price target on Salesforce to $200 while keeping an Outperform rating after the company's Q2 earnings beat and raised FY20 guidance. The analyst cites "little meaningful competition" and no evidence of pricing pressure or market saturation at Salesforce, saying its current valuation of 5.5-times enterprise value to expected 2021 revenue represents a "buying opportunity". Zukin is also positive on the company's "uniquely strong" CEO steering Salesforce to become a "System of Customer Intelligence".
08/23/19
BARD
08/23/19
NO CHANGE
Target $175
BARD
Outperform
Salesforce remains best way to play Digital Transformation, says Baird
Baird analyst Rob Oliver said the Salesforce Q2 results will likely be a relief to investors who worried about the broader macro environment, recent pace of acquisitions, competition, and foreign exchange headwinds. The analyst said Digital Transformation remains a massive driver for Salesforce and it remains the best way to play that theme. Olive reiterated his Outperform rating and $175 price target on Salesforce shares.
08/23/19
RHCO
08/23/19
NO CHANGE
Target $195
RHCO
Buy
Salesforce price target raised to $195 from $189 at SunTrust
SunTrust analyst Terry Tillman raised his price target on Salesforce to $195 and kept his Buy rating after its "solid" Q2 results with upside in a "number of key metrics". The analyst notes the raised guidance was also supported by the timing of recent acquisitions, and he boosts his FY20 and FY21 earnings estimates by 13c and 4c to $2.83 and $3.03 respectively. Tillman adds that the valuation on Salesforce at 8-times his expected 2020 revenue estimate is in line with the 20%-30% growth peer group.

TODAY'S FREE FLY STORIES

EEFT

Euronet

$147.35

0.92 (0.63%)

12:27
09/20/19
09/20
12:27
09/20/19
12:27
Conference/Events
Euronet participates in a conference call with Northland »

Conference call with CEO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 14

    Nov

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$300.20

0.523619 (0.17%)

12:27
09/20/19
09/20
12:27
09/20/19
12:27
Hot Stocks
Trump says China buying ag products not enough for trade deal »

President Trump said in…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$300.20

0.523619 (0.17%)

ADM

Archer Daniels

$41.10

0.21 (0.51%)

AGU

Agrium

$0.00

(0.00%)

CF

CF Industries

$49.97

-0.07 (-0.14%)

MON

Bought by BAYRY

$0.00

(0.00%)

POT

Potash

$0.00

(0.00%)

ANDE

Andersons

$26.45

-0.39 (-1.45%)

SYT

Syngenta

$0.00

(0.00%)

BG

Bunge

$56.02

-0.15 (-0.27%)

IPI

Intrepid Potash

$3.41

-0.01 (-0.29%)

CMP

Compass Minerals

$57.07

-0.985 (-1.70%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 06

    Nov

  • 13

    Nov

REGN

Regeneron

$295.39

9.11 (3.18%)

12:25
09/20/19
09/20
12:25
09/20/19
12:25
Options
Regeneron call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FTCH

Farfetch

$8.95

0.04 (0.45%)

12:25
09/20/19
09/20
12:25
09/20/19
12:25
Conference/Events
Cowen retail/luxury analyst to hold an analyst/industry conference call »

Retail & Luxury Goods…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

12:25
09/20/19
09/20
12:25
09/20/19
12:25
Conference/Events
Cantor Fitzgerald healthcare analysts to hold analyst/industry conference call »

Healthcare Analysts host…

MGI

MoneyGram

$4.94

0.075 (1.54%)

12:24
09/20/19
09/20
12:24
09/20/19
12:24
Conference/Events
MoneyGram participates in a conference call with Northland »

Conference call with CEO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

YCBD

cbdMD

$5.03

0.31 (6.57%)

12:19
09/20/19
09/20
12:19
09/20/19
12:19
Hot Stocks
Breaking Hot Stocks news story on cbdMD »

cbdMD trading halted,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

12:17
09/20/19
09/20
12:17
09/20/19
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

12:16
09/20/19
09/20
12:16
09/20/19
12:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SONO

Sonos

$15.01

-0.065 (-0.43%)

12:15
09/20/19
09/20
12:15
09/20/19
12:15
Options
Sonos put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MRAM

Everspin Technologies

$6.52

-0.09 (-1.36%)

12:12
09/20/19
09/20
12:12
09/20/19
12:12
Conference/Events
Everspin Technologies management to meet with Needham »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 27

    Sep

  • 12

    Nov

SAIC

SAIC

$84.64

0.76 (0.91%)

12:11
09/20/19
09/20
12:11
09/20/19
12:11
Recommendations
SAIC analyst commentary  »

SAIC recompete bid on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALNY

Alnylam

$86.18

1.5 (1.77%)

12:11
09/20/19
09/20
12:11
09/20/19
12:11
Conference/Events
Alnylam management to meet with Needham »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

  • 02

    Oct

  • 04

    Feb

SNPS

Synopsys

$137.26

0.09 (0.07%)

12:10
09/20/19
09/20
12:10
09/20/19
12:10
Conference/Events
Synopsys management to meet with Needham »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 27

    Sep

TYL

Tyler Technologies

$259.35

-0.22 (-0.08%)

12:10
09/20/19
09/20
12:10
09/20/19
12:10
Conference/Events
Tyler Technologies management to meet with JMP Securities »

Meeting to be held in San…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 26

    Sep

AAPL

Apple

$220.96

0.05 (0.02%)

, MCD

McDonald's

$210.55

-0.01 (-0.00%)

12:02
09/20/19
09/20
12:02
09/20/19
12:02
On The Fly
Fly Intel: Wall Street's top stories at midday »

Stocks are mixed at…

AAPL

Apple

$220.96

0.05 (0.02%)

MCD

McDonald's

$210.55

-0.01 (-0.00%)

FB

Facebook

$190.17

0.02 (0.01%)

MDR

McDermott

$2.70

1.12 (70.89%)

CRC

California Resources

$11.86

1.96 (19.80%)

ROKU

Roku

$114.30

-19.41 (-14.52%)

W

Wayfair

$123.39

-5.275 (-4.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 23

    Sep

  • 24

    Sep

  • 27

    Oct

SCS

Steelcase

$18.34

1.57 (9.36%)

12:00
09/20/19
09/20
12:00
09/20/19
12:00
Hot Stocks
Steelcase rises 9.6% »

Steelcase is up 9.6%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 15

    Oct

  • 16

    Oct

IBN

ICICI Bank

$11.88

1.11 (10.31%)

12:00
09/20/19
09/20
12:00
09/20/19
12:00
Hot Stocks
ICICI Bank rises 10.2% »

ICICI Bank is up 10.2%,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRC

California Resources

$11.75

1.85 (18.69%)

12:00
09/20/19
09/20
12:00
09/20/19
12:00
Hot Stocks
California Resources rises 18.8% »

California Resources is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNY

Sanofi

$45.72

0.83 (1.85%)

11:54
09/20/19
09/20
11:54
09/20/19
11:54
Upgrade
Sanofi rating change  »

Morgan Stanley upgrades…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 27

    Sep

  • 02

    Oct

TSLA

Tesla

$242.92

-3.59 (-1.46%)

11:50
09/20/19
09/20
11:50
09/20/19
11:50
Options
Bearish Dec put spread collar in Tesla opened for a small debit »

Bearish Dec put spread…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

SNY

Sanofi

$45.61

0.72 (1.60%)

11:46
09/20/19
09/20
11:46
09/20/19
11:46
Upgrade
Sanofi rating change  »

Sanofi upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 27

    Sep

  • 02

    Oct

CRZBY

Commerzbank

$0.00

(0.00%)

11:46
09/20/19
09/20
11:46
09/20/19
11:46
Hot Stocks
Commerzbank develops draft of new strategy, to cut 4,300 jobs »

Commerzbank announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RHHBY

Roche

$0.00

(0.00%)

11:45
09/20/19
09/20
11:45
09/20/19
11:45
Hot Stocks
Roche reports FDA approves cobas Babesia test »

Roche announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Nov

PBR

Petrobras

$14.44

-0.09 (-0.62%)

11:42
09/20/19
09/20
11:42
09/20/19
11:42
Periodicals
Petrobras suffers increase in fuel theft from pipelines, Reuters reports »

Petrobras is confronting…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.